Formulary Search - PAD Formulary

PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search

BNF Chapter

BNF Paragraph

Please select a BNF Chapter.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Acid Suppression (Children) (Omeprazole - Acid Suppression (Children))

Records returned : 8 (on 21 Nov 2024 at 22:56:30). Return to search results for ' Acid Suppression (Children) '.

Drug

Indication

Status

Trust Alignment

Links

Restrictions/Comments

01.03.05

Omeprazole

Acid Suppression (Children)

Green

Formulations :

Capsules

ASPH

RSFT

SASH

SABP

Primary Care

Guidelines BNF SPC

Important

Preferred

1st line option in children who are able to swallow capsules. Most capsules can also be opened and mixed with water or fruit juice (licensed).

01.03.05

Acid Suppression (Children)

Green (see narrative)

Formulations :

Dispersible tablets

ASPH

RSFT

SASH

SABP

Primary Care

Guidelines BNF SPC

Important

Mezzopram is the preferred brand - smaller granule size. Omeprazole MUPS is an alternative. Disperse in water then mix with juice, apple sauce or yoghurt

01.03.05

Acid Suppression (Children)

Blue

Formulations :

Oral suspension

ASPH

RSFT

SASH

SABP

Primary Care

Guidelines BNF SPC

Important

Only for children under 10kg and/or with a feeding tube less than 8Fr

01.03.05

Acid Suppression (Children)

Red

Formulations :

Powder

ASPH

RSFT

SASH

SABP

Primary Care

Guidelines BNF SPC

Important

Aclomep powder - ASPH NICU only

01.03.05

Acid Suppression (Children)

Non Formulary

Formulations :

Tablets

ASPH

RSFT

SASH

SABP

Primary Care

Guidelines BNF SPC

NFD1

01.03.05

Lansoprazole

Acid Suppression (Children)

Green (see narrative)

Formulations :

Capsules

ASPH

RSFT

SASH

SABP

Primary Care

Guidelines BNF SPC

Important

2nd line treatment option in children who are able to swallow capsules. Some capsules are licensed to be opened and have their contents mixed with water, apple/tomato juice or sprinkled on soft food (e.g. yoghurt, apple puree)

01.03.05

Acid Suppression (Children)

Green (see narrative)

Formulations :

Oro-dispersible

ASPH

RSFT

SASH

SABP

Primary Care

Guidelines BNF SPC

Important

2nd line treatment option in children unable to swallow omeprazole or lansoprazole capsules. Oro-dispersible tablets disperse in the mouth to release gastro-resistant granules. Lansoprazole is NOT absorbed sublingually. The gastro-resistant granules must be swallowed for the medicine to be effective. The FasTabs® can also be administered in apple or orange juice.

01.03.05

Esomeprazole

Acid Suppression (Children)

Green (see narrative)

Formulations :

Granules

ASPH

RSFT

SASH

SABP

Primary Care

Guidelines BNF SPC

Important

Branded Nexium granules for children/infants with enteral feeding tubes (6Fr or larger). Off-label use in infants under 1 year. Generic granules 3rd line in children/infants under 1 year without an NG tube. Refer to PPI algorithm for details.

For information about the icons and status values within this site, please refer to the keys below.

Icon/Links Key

NFD1

Non formulary

NFD2

Not assessed for formulary status. Apply to APC / DTC before use.

Controlled drug. Prescribing and/or storage requirements may apply

Restrictions apply

Safety Alert

Unlicensed - no UK marketing license in place

Off-label use. Not licensed for this indication.

NHSE

Treatment commissioned by NHS England

CDF

ICB

Treatment commissioned by the ICB

BlueTeq

BlueTeq form to be completed

NICE

Traffic Light Status Key

Red

Specialist ONLY drugs - treatment initiated and continued by specialist clinicians

Amber

Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement

Green

GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.

Black

Now referred to as "Non Formulary" but some BLACK drugs remain pending review. Not recommended for use in any health setting across Surrey and NW Sussex health economy.

Amber Star

Now referred to as "Blue" but some Amber Star drugs remain pending review. Prescribing initiated and stabliised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.

Green (see narrative)

GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.

Non Formulary

Not recommended for use in any health setting across Surrey and NW Sussex health economy. (Formerly BLACK traffic light status)

See Below

Please add a description.

N/A

Please add a description.

Blue

Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.

Green - Black

Now referred to as "Do not initiate in new patients" but some GREEN/BLACK drugs remain pending review. These drugs are NOT for new initiations (BLACK, (now referred to as Non Formulary)) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required.

See narrative

See narrative - is applied in instances where there may be more than one traffic light status for a drug. This occurs when the traffic light status may differ between specific cohorts of patients e.g. those of childbearing potential and those who are not (in the case of sodium valproate)

Do not initiate in new patients

These drugs are NOT for new initiations (Non Formulary) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required. (Formerly GREEN/BLACK traffic light status)